ViGenCell

ViGenCell EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of ViGenCell (308080.KQ) as of Oct 19, 2026 is -11.64. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -11.40 — a change of 2.05% (lower).

EV/FCF

-11.64

YoY

2.05%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of ViGenCell is 2025 -11.64 . EV/FCF (Enterprise Value to Free Cash Flow) of ViGenCell was 2024 -11.40 . It decreases by 2.05% lower compared to the previous year.

The ViGenCell EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-44.05 KRW
Jan 1, 2020
-18.75 KRW
Jan 1, 2021
-5.49 KRW
Jan 1, 2022
-4.09 KRW
Jan 1, 2023
-7.18 KRW
Jan 1, 2024
-11.40 KRW
Jan 1, 2025
-11.64 KRW
The ViGenCell EV/FCF history
YEAREV/FCFYoY
-11.64+2.05%
-11.40+58.78%
-7.18+75.42%
-4.09-25.39%
-5.49-70.73%
-18.75-57.44%
-44.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViGenCell Stock analysis

What does ViGenCell do? ViGenCell Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company has 80 employees and completed its initial public offering (IPO) on August 25, 2021. ViGenCell focuses on research and development in natural science and engineering, with a particular emphasis on cell therapy technologies. The company develops and manufactures immuno-cancer cell therapy products and immunosuppressive cell therapy products. It also provides the Vitier platform, which is an antigen-specific killing T cell treatment, the Viranger platform for gamma delta T cell gene therapy, and the Vimedier platform-based technology for myeloid suppressor cell therapy derived from umbilical cord blood. ViGenCell is engaged in the research and development of new drugs targeting conditions such as acute myeloid leukemia (AML) and glioblastoma. The company's website is https://www.vigencell.com/. ViGenCell Inc is listed on the Korean stock market under the ticker 308080.KQ and has the ISIN KR7308080001. The company's headquarters are located in Seoul, South Korea. ViGenCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViGenCell stock

EV/FCF (Enterprise Value to Free Cash Flow) of ViGenCell is -11.64 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of ViGenCell changed from -11.40 to -11.64, representing a 2.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) ViGenCell since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s ViGenCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ViGenCell

All Key Metrics — ViGenCell